Azelastine/fluticasone propionate - Cipla/Meda

Drug Profile

Azelastine/fluticasone propionate - Cipla/Meda

Alternative Names: Azelastine hydrochloride/fluticasone propionate; Duonase; Dymista; Dymistalan; Dymistin; Dymolin; Fluticasone propionate/azelastine hydrochloride; Flutista; MP 29-01; MP 29-02; MP-AzeFlu

Latest Information Update: 03 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meda
  • Developer Cipla; Meda
  • Class Antiallergics; Glucocorticoids; Phthalazines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 29 Jul 2018 MEDA Pharma initiates enrolment in the DYNAS-CHI phase III trial for Allergic Rhinitis in China (NCT03599791)
  • 02 Mar 2018 Pharmacodynamics data from a preclinical trial in Allergic rhinitis presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2018)
  • 29 Sep 2017 USPTO grants a petition for inter partes review (IPR) filed by Argentum Pharmaceuticals and KVK Tech against challenged claims of last-expiring patent of azelastine hydrochloride/fluticasone propionate nasal spray
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top